Remove 2029 Remove IT Remove Patients Remove Provider
article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog

While the dates have been written in the law, the previous extensions provided a reasonable hope that the program would continue. This bill would extend the designation deadline until September 30, 2029, a five-year extension (and would require yet another GAO report). The program, however, has always had a scheduled sunset date.

article thumbnail

Landmark Drug Pricing Bill Set to Become Law; HP&M Releases Summary Slide Deck

FDA Law Blog

The number will begin in 2026 with 10 drug covered under Medicare Part D and will increase annually to 20 Part B and 20 Part D drugs by 2029 and thereafter, with the selected drugs accumulating from year to year. Manufacturers receive no benefits in exchange for the inflation rebates.